bioAffinity Technologies announced notification of patent allowance from Mexico's Institute of Industrial Property for methods using flow cytometry and antibodies to detect lung cancer. The patent strengthens the company's global IP portfolio for its CyPath Lung diagnostic platform across multiple jurisdictions.